Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Arbutus Biopharma Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ARBUTUS AND ITS EXCLUSIVE LICENSEE, GENEVANT, FILED THREE INTERNATIONAL LAWSUITS SEEKING TO ENFORCE PATENTS PROTECTING THEIR INNOVATIVE LIPID NANOPARTICLE (LNP) TECHNOLOGY AGAINST PFIZER AND BIONTECH

ARBUTUS INITIATES INTERNATIONAL PATENT INFRINGEMENT ENFORCEMENT ACTIONS AGAINST PFIZER AND BIONTECH, RECEIVES FIRST PAYMENT FROM MODERNA SETTLEMENT AGREEMENT AND ANNOUNCES INTENT TO RETURN CAPITAL TO SHAREHOLDERS

Q1 TOTAL REVENUE OF $179.1M INCLUDES ESTIMATED LICENSE REVENUE FROM GENEVANT RELATED TO LITIGATION SETTLEMENT WITH MODERNA

ARBUTUS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

FAST TRACK DESIGNATION HAS THE POTENTIAL TO FACILITATE DEVELOPMENT AND ACCELERATE FDA REVIEW OF IMDUSIRAN WARMINSTER, PA., APRIL 15, 2026 (GLOBE NEWSWIRE) -- ARBUTUS BIOPHARMA CORPORATION (NASDAQ: ABUS) (ARBUTUS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON INFECTIOUS DISEASE, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED FAST TRACK DESIGNATION FOR IMDUSIRAN FOR THE TREATMENT OF CHRONIC HEPATITIS B (CHBV).

ARBUTUS RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR IMDUSIRAN FOR THE TREATMENT OF CHRONIC HEPATITIS B

STRONG FINANCIAL POSITION WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $91.5M AS OF DECEMBER 2025

ARBUTUS REPORTS FOURTH QUARTER AND YEAR END 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

MODERNA TO PAY GENEVANT AND ARBUTUS $950 MILLION UPFRONT AND AN ADDITIONAL $1.3 BILLION CONTINGENT UPON A FAVORABLE RESOLUTION OF MODERNA'S SECTION 1498 APPEAL IF THE $1.3 BILLION PAYMENT IS REALIZED, THIS SETTLEMENT WILL BE THE LARGEST DISCLOSED PATENT SETTLEMENT PAID IN THE PHARMACEUTICAL INDUSTRY AND THE SECOND LARGEST IN ANY INDUSTRY SETTLEMENT HOLDS MODERNA ACCOUNTABLE FOR INFRINGEMENT AND PROVIDES FOR THE COURT TO ENTER JUDGMENT OF NO INVALIDITY ON THE FOUR GENEVANT/ARBUTUS PATENTS ASSERTED IN THE CASE GENEVANT GRANTS MODERNA A GLOBAL NON-EXCLUSIVE LICENSE TO ITS LNP DELIVERY TECHNOLOGY FOR SM-102-CONTAINING MRNA VACCINES FOR INFECTIOUS DISEASE AND A COVENANT NOT TO SUE FOR CERTAIN GENEVANT/ARBUTUS PATENTS AND MODERNA PRODUCTS, ENDING ALL PATENT-INFRINGEMENT LITIGATION AGAINST MODERNA ARISING FROM ITS UNAUTHORIZED USE OF THE TECHNOLOGY IN ITS COVID-19 VACCINES PFIZER/BIONTECH LITIGATION IS ONGOING IN THE UNITED STATES FOLLOWING A FAVORABLE MARKMAN RULING ISSUED IN SEPTEMBER 2025; COMIRNATY SALES REPRESENT ~2/3 OF GLOBAL COVID-MRNA VACCINE SALES TO DATE ROIVANT'S BOARD OF DIRECTORS HAS APPROVED A $1 BILLION SHARE REPURCHASE PROGRAM, INCLUSIVE OF THE $500 MILLION AUTHORIZATION THAT WAS APPROVED IN JUNE 2025 ROIVANT WILL HOST AN INVESTOR CALL TO DISCUSS THESE UPDATES TODAY, MARCH 3, 2026, AT 4:45 P.M. ET BASEL, SWITZERLAND AND LONDON AND NEW YORK, MARCH 03, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY ANNOUNCED THAT GENEVANT SCIENCES, A LEADING NUCLEIC ACID DELIVERY COMPANY WITH WORLD-CLASS PLATFORMS AND A ROBUST LIPID NANOPARTICLE (LNP) PATENT PORTFOLIO AND A SUBSIDIARY OF ROIVANT, AND ARBUTUS BIOPHARMA CORPORATION (NASDAQ: ABUS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON INFECTIOUS DISEASE, HAVE ENTERED INTO A $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA, INC. TO RESOLVE ALL U.S. AND INTERNATIONAL ENFORCEMENT ACTIONS INVOLVING MODERNA'S UNAUTHORIZED USE OF GENEVANT'S AND ARBUTUS' LNP DELIVERY TECHNOLOGY IN ITS COVID-19 VACCINES, INCLUDING S

ROIVANT ANNOUNCES GENEVANT SCIENCES' AND ARBUTUS BIOPHARMA'S $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA

MODERNA TO PAY GENEVANT AND ARBUTUS $950 MILLION UPFRONT AND AN ADDITIONAL $1.3 BILLION CONTINGENT UPON A FAVORABLE RESOLUTION OF MODERNA'S SECTION 1498 APPEAL IF THE $1.3 BILLION PAYMENT IS REALIZED, THIS SETTLEMENT WILL BE THE LARGEST DISCLOSED PATENT SETTLEMENT PAID IN THE PHARMACEUTICAL INDUSTRY AND THE SECOND LARGEST IN ANY INDUSTRY SETTLEMENT HOLDS MODERNA ACCOUNTABLE FOR INFRINGEMENT AND PROVIDES FOR THE COURT TO ENTER JUDGMENT OF NO INVALIDITY ON THE FOUR GENEVANT/ARBUTUS PATENTS ASSERTED IN THE CASE GENEVANT GRANTS MODERNA A GLOBAL NON-EXCLUSIVE LICENSE TO ITS LNP DELIVERY TECHNOLOGY FOR SM-102-CONTAINING MRNA VACCINES FOR INFECTIOUS DISEASE AND A COVENANT NOT TO SUE FOR CERTAIN GENEVANT/ARBUTUS PATENTS AND MODERNA PRODUCTS, ENDING ALL PATENT-INFRINGEMENT LITIGATION AGAINST MODERNA ARISING FROM ITS UNAUTHORIZED USE OF THE TECHNOLOGY IN ITS COVID-19 VACCINES PFIZER/BIONTECH LITIGATION IS ONGOING IN THE UNITED STATES FOLLOWING A FAVORABLE MARKMAN RULING ISSUED IN SEPTEMBER 2025; COMIRNATY SALES REPRESENT ~2/3 OF GLOBAL COVID-MRNA VACCINE SALES TO DATE ARBUTUS ANNOUNCES THAT IT IS CURRENTLY EVALUATING A RETURN OF CAPITAL TO SHAREHOLDERS FOR THE THIRD QUARTER OF CALENDAR YEAR 2026, IN CONJUNCTION WITH THE UPFRONT PAYMENT ROIVANT WILL HOST AN INVESTOR CALL TO DISCUSS THESE UPDATES TODAY, MARCH 3, 2026, AT 4:45 P.M. ET BASEL, SWITZERLAND AND VANCOUVER, BRITISH COLUMBIA, MARCH 03, 2026 (GLOBE NEWSWIRE) -- GENEVANT SCIENCES, A LEADING NUCLEIC ACID DELIVERY COMPANY WITH WORLD-CLASS PLATFORMS AND A ROBUST LIPID NANOPARTICLE (LNP) PATENT PORTFOLIO AND A SUBSIDIARY OF ROIVANT SCIENCES LTD.

GENEVANT SCIENCES AND ARBUTUS BIOPHARMA ANNOUNCE $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA

MODERNA TO PAY $950 MILLION WITH NO FUTURE ROYALTIES TO RESOLVE ALL GLOBAL LITIGATION; CORRESPONDING CHARGE EXPECTED IN Q1 2026 DISTRICT COURT'S SECTION 1498 DECISION TO BE APPEALED TO THE FEDERAL CIRCUIT COURT OF APPEALS WITH POTENTIAL ADDITIONAL PAYMENT CONTINGENT ON THE OUTCOME; NO ACCRUAL RECORDED FOR POTENTIAL ADDITIONAL PAYMENT AS LOSS IS NOT CONSIDERED PROBABLE 2026 YEAR-END CASH AND CASH EQUIVALENTS NOW EXPECTED TO BE IN THE RANGE OF $4.5 - $5.0 BILLION CAMBRIDGE, MA / ACCESS NEWSWIRE / MARCH 3, 2026 / MODERNA, INC. (NASDAQ:MRNA) TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SETTLEMENT AGREEMENT WITH ARBUTUS BIOPHARMA CORPORATION AND GENEVANT SCIENCES GMBH RESOLVING ALL LITIGATION WORLDWIDE, INCLUDING BETWEEN THE PARTIES IN THE U.S. DISTRICT COURT FOR THE DISTRICT OF DELAWARE. THE SETTLEMENT RESOLVES ALL WORLDWIDE ARBUTUS/GENEVANT LITIGATION RELATED TO SPIKEVAX AND MRESVIA AND PROVIDES CERTAINTY GOING FORWARD FOR MODERNA'S FULL INFECTIOUS DISEASE PORTFOLIO, INCLUDING MNEXSPIKE, MCOMBRIAX AND ITS FUTURE VACCINE PIPELINE, WITH NO FUTURE ROYALTIES OWED.

MODERNA RESOLVES GLOBAL PATENT LITIGATION WITH ARBUTUS/GENEVANT

STRONG FINANCIAL POSITION WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $93.7M   MODERNA LITIGATION U.S. TRIAL SCHEDULED FOR MARCH 2026; FAVORABLE CLAIM CONSTRUCTION RULING IN PFIZER-BIONTECH LITIGATION ISSUED IN SEPTEMBER 2025   ADDITIONAL ANALYSIS OF IMDUSIRAN (AB-729) CLINICAL DATA SHOWS: - 46% OF PHASE 2A PATIENTS MET CRITERIA TO DISCONTINUE ALL TREATMENT - 94% OF LONG-TERM FOLLOW-UP PATIENTS REMAIN OFF ALL TREATMENT FOR UP TO 2+ YEARS - 100% OF HBV DNA POSITIVE PATIENTS IN PHASE 1B ACHIEVED HBV DNA LEVELSBELOWQUANTIFICATION AFTER ONLY 18 WEEKS OF IMDUSIRAN AND NUCLEOS(T)IDE ANALOGUE THERAPY - ALL HBV E-ANTIGEN POSITIVE PATIENTS DEMONSTRATED DOSE-DEPENDENT HBV E-ANTIGEN DECREASES   WARMINSTER, PA., NOV. 13, 2025 (GLOBE NEWSWIRE) -- ARBUTUS BIOPHARMA CORPORATION (NASDAQ: ABUS) (ARBUTUS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON INFECTIOUS DISEASE, TODAY REPORTED THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDED A CORPORATE UPDATE.

ARBUTUS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

MULTIPLE ABSTRACTS ACCEPTED FEATURING IMDUSIRAN CLINICAL DATA HIGHLIGHTING PROGRESS TOWARD A POTENTIAL FUNCTIONAL CURE FOR CHRONIC HEPATITIS B VIRUS AB-101 CLINICAL DATA ABSTRACT RECOGNIZED AS A POSTER OF DISTINCTION WARMINSTER, PA., OCT. 07, 2025 (GLOBE NEWSWIRE) -- ARBUTUS BIOPHARMA CORPORATION (NASDAQ: ABUS) (ARBUTUS OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON INFECTIOUS DISEASE, TODAY ANNOUNCED THAT THREE ABSTRACTS FEATURING IMDUSIRAN DATA AND ONE ABSTRACT FEATURING AB-101 DATA, HAVE BEEN ACCEPTED FOR POSTER PRESENTATIONS AT THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES (AASLD)  THE LIVER MEETING 2025, TAKING PLACE NOVEMBER 711 IN WASHINGTON, DC.

ARBUTUS ANNOUNCES FOUR ABSTRACTS ACCEPTED FOR PRESENTATION AT AASLD - THE LIVER MEETING 2025

Q2 TOTAL REVENUE OF $10.7M INCLUDES PREVIOUSLY-DEFERRED REVENUE FOLLOWING REACQUISITION OF GREATER CHINA RIGHTS TO IMDUSIRAN

Arbutus Biopharma Corporation

ABUS

Price

Financial Reports

No items found.

Press Releases

Arbutus Biopharma Corporation

ABUS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ABUS